LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 544

Search options

  1. Book: Cancer drug delivery systems based on the tumor microenvironment

    Matsumura, Yasuhiro / Tarin, David

    2019  

    Author's details Yasuhiro Matsumura, David Tarin editors
    Keywords Pharmaceutical technology ; Cancer research ; Nanoscale science ; Nanoscience ; Nanostructures
    Subject code 615.19
    Language English
    Size xi, 325 Seiten, Illustrationen
    Publisher Springer
    Publishing place Tokyo
    Publishing country Japan
    Document type Book
    HBZ-ID HT020379041
    ISBN 978-4-431-56878-0 ; 9784431568803 ; 4-431-56878-6 ; 4431568808
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2020 A 281 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Inadequate therapeutic responses to glucocorticoid treatment in bronchial asthma

    Yasuhiro Matsumura

    Journal of International Medical Research, Vol

    2023  Volume 51

    Abstract: Bronchial asthma (BA) is a heterogeneous disease. Some patients benefit greatly from glucocorticoid (GC) treatment, whereas others are non-responders. This could be attributable to differences in pathobiology. Thus, predicting the responses to GC ... ...

    Abstract Bronchial asthma (BA) is a heterogeneous disease. Some patients benefit greatly from glucocorticoid (GC) treatment, whereas others are non-responders. This could be attributable to differences in pathobiology. Thus, predicting the responses to GC treatment in patients with BA is necessary to increase the success rates of GC therapy and avoid adverse effects. The sustained inflammation in BA decreases glucocorticoid receptor (GR, NR3C1) function. Meanwhile, GRβ overexpression might contribute to GC resistance. Important factors in decreased GR function include p38 mitogen-activated protein kinase-dependent GR phosphorylated at Ser226, reduced expression of histone deacetylase 2 following activation of the phosphatidylinositol 3-kinase-δ signaling pathway, and increased nuclear factor-kappa B activity. MicroRNAs, which are involved in GC sensitivity, are considered biomarkers of the response to inhaled GCs. Some studies revealed that inflammatory phenotypes and disease-related modifiable factors, including infections, the airway microbiome, mental stress, smoking, and obesity, regulate individual sensitivity to GCs. Therefore, future investigations are warranted to improve treatment outcomes.
    Keywords Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher SAGE Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Inadequate therapeutic responses to glucocorticoid treatment in bronchial asthma.

    Matsumura, Yasuhiro

    The Journal of international medical research

    2023  Volume 51, Issue 6, Page(s) 3000605231175746

    Abstract: Bronchial asthma (BA) is a heterogeneous disease. Some patients benefit greatly from glucocorticoid (GC) treatment, whereas others are non-responders. This could be attributable to differences in pathobiology. Thus, predicting the responses to GC ... ...

    Abstract Bronchial asthma (BA) is a heterogeneous disease. Some patients benefit greatly from glucocorticoid (GC) treatment, whereas others are non-responders. This could be attributable to differences in pathobiology. Thus, predicting the responses to GC treatment in patients with BA is necessary to increase the success rates of GC therapy and avoid adverse effects. The sustained inflammation in BA decreases glucocorticoid receptor (GR, NR3C1) function. Meanwhile, GRβ overexpression might contribute to GC resistance. Important factors in decreased GR function include p38 mitogen-activated protein kinase-dependent GR phosphorylated at Ser226, reduced expression of histone deacetylase 2 following activation of the phosphatidylinositol 3-kinase-δ signaling pathway, and increased nuclear factor-kappa B activity. MicroRNAs, which are involved in GC sensitivity, are considered biomarkers of the response to inhaled GCs. Some studies revealed that inflammatory phenotypes and disease-related modifiable factors, including infections, the airway microbiome, mental stress, smoking, and obesity, regulate individual sensitivity to GCs. Therefore, future investigations are warranted to improve treatment outcomes.
    MeSH term(s) Humans ; Glucocorticoids/therapeutic use ; Receptors, Glucocorticoid/genetics ; Receptors, Glucocorticoid/metabolism ; Asthma/genetics ; NF-kappa B/metabolism ; Signal Transduction ; Inflammation/drug therapy
    Chemical Substances Glucocorticoids ; Receptors, Glucocorticoid ; NF-kappa B
    Language English
    Publishing date 2023-06-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 184023-x
    ISSN 1473-2300 ; 0300-0605 ; 0142-2596
    ISSN (online) 1473-2300
    ISSN 0300-0605 ; 0142-2596
    DOI 10.1177/03000605231175746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: 35 years of discussions with Prof. Maeda on the EPR effect and future directions.

    Matsumura, Yasuhiro

    Journal of controlled release : official journal of the Controlled Release Society

    2022  Volume 348, Page(s) 966–969

    Abstract: In May 2021, 35 years after first announcing the enhanced permeability and retention (EPR) effect, Dr. Maeda passed away. As a theoretical pillar of high molecular weight drug delivery systems (DDS) with high biocompatibility, the EPR effect has been ... ...

    Abstract In May 2021, 35 years after first announcing the enhanced permeability and retention (EPR) effect, Dr. Maeda passed away. As a theoretical pillar of high molecular weight drug delivery systems (DDS) with high biocompatibility, the EPR effect has been proven worldwide in experimental mouse models. However, in clinical solid tumors, awareness of the EPR effect is insufficient, and more importantly, DDS has not become the mainstream cancer treatment. Both Dr. Maeda and I were acutely aware of this, and for 35 years, we discussed what to do about it and strived to make up for the inadequacies of the EPR effect by employing different strategies. Dr. Maeda came up with ways to use tumor vascular permeability more effectively and to apply oxidative stress to tumor cells. I proposed cancer stromal targeting (CAST) therapy using the anti-insoluble fibrin antibody conjugated with an anticancer agent in order to overcome the insufficiency of the EPR effect in clinical solid cancers, which possess abundant stromal tissue. Clinical cancers are surrounded by an abundant stroma and survive even under hypoxia and malnutrition due to this stromal barrier. Cancer cells become resistant to any external attack, including with anticancer drugs and radiation. While it goes without saying that EPR effects are important in clinical solid cancer strategies, DDSs that offer both accumulation and even distribution in solid cancers are also required.
    MeSH term(s) Animals ; Antineoplastic Agents/therapeutic use ; Drug Delivery Systems ; Immunoconjugates/therapeutic use ; Mice ; Neoplasms/pathology ; Permeability
    Chemical Substances Antineoplastic Agents ; Immunoconjugates
    Language English
    Publishing date 2022-07-01
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632533-6
    ISSN 1873-4995 ; 0168-3659
    ISSN (online) 1873-4995
    ISSN 0168-3659
    DOI 10.1016/j.jconrel.2022.06.035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2055: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Barriers to antibody therapy in solid tumors, and their solutions.

    Matsumura, Yasuhiro

    Cancer science

    2021  Volume 112, Issue 8, Page(s) 2939–2947

    Abstract: Antibody drugs have become the mainstream of cancer treatment due to advances in cancer biology and Ab engineering. However, several barriers to Ab therapy have also been identified. These include various mechanisms for Ab drug resistance, such as ... ...

    Abstract Antibody drugs have become the mainstream of cancer treatment due to advances in cancer biology and Ab engineering. However, several barriers to Ab therapy have also been identified. These include various mechanisms for Ab drug resistance, such as heterogeneity of antigen expression in tumor cells and reduction in antitumor immunity due to expression diversity, polymorphism of Fc receptors (FcR) in effector cells, and reduced function of effector cells. Countermeasures to each resistance mechanism are being investigated. This review focuses on barriers that impede the delivery of Ab drugs due to features of the solid tumor microenvironment. Unlike hematological malignancies, in which the target tumor cells are in blood vessels, clinical solid tumors contain cancer stroma, which interferes with the delivery of Ab drugs. In addition, the cancer mass itself interferes with the penetration of Ab drugs. In this article, I will consider the etiology of cancer stroma and propose a new Ab drug development strategy for solid cancer treatment centering on cancer stromal targeting (CAST) therapy using anti-insoluble fibrin Ab-drug conjugate (ADC), which can overcome the cancer stroma barrier. The recent success of ADCs, chimeric antigen receptor T cells (CAR-Ts), and Bi-specific Abs is changing the category of Ab drugs from molecular-targeted drugs based on growth signal inhibition to cancer-specific targeted therapies. Therefore, at the end of this review, I argue that it is time to reorient the concept of Ab drug development.
    MeSH term(s) Antineoplastic Agents, Immunological/chemistry ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Drug Design ; Drug Resistance, Neoplasm ; Humans ; Models, Molecular ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/immunology ; Polymorphism, Genetic ; Protein Engineering ; Receptors, Fc/genetics ; Tumor Microenvironment/drug effects
    Chemical Substances Antineoplastic Agents, Immunological ; Receptors, Fc
    Language English
    Publishing date 2021-06-24
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2115647-5
    ISSN 1349-7006 ; 1347-9032
    ISSN (online) 1349-7006
    ISSN 1347-9032
    DOI 10.1111/cas.14983
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: 35 years of discussions with Prof. Maeda on the EPR effect and future directions

    Matsumura, Yasuhiro

    Journal of controlled release. 2022 June 20,

    2022  

    Abstract: In May 2021, 35 years after first announcing the enhanced permeability and retention (EPR) effect, Dr. Maeda passed away. As a theoretical pillar of high molecular weight drug delivery systems (DDS) with high biocompatibility, the EPR effect has been ... ...

    Abstract In May 2021, 35 years after first announcing the enhanced permeability and retention (EPR) effect, Dr. Maeda passed away. As a theoretical pillar of high molecular weight drug delivery systems (DDS) with high biocompatibility, the EPR effect has been proven worldwide in experimental mouse models. However, in clinical solid tumors, awareness of the EPR effect is insufficient, and more importantly, DDS has not become the mainstream cancer treatment. Both Dr. Maeda and I were acutely aware of this, and for 35 years, we discussed what to do about it and strived to make up for the inadequacies of the EPR effect by employing different strategies. Dr. Maeda came up with ways to use tumor vascular permeability more effectively and to apply oxidative stress to tumor cells. I proposed cancer stromal targeting (CAST) therapy using the anti-insoluble fibrin antibody conjugated with an anticancer agent in order to overcome the insufficiency of the EPR effect in clinical solid cancers, which possess abundant stromal tissue. Clinical cancers are surrounded by an abundant stroma and survive even under hypoxia and malnutrition due to this stromal barrier. Cancer cells become resistant to any external attack, including with anticancer drugs and radiation. While it goes without saying that EPR effects are important in clinical solid cancer strategies, DDSs that offer both accumulation and even distribution in solid cancers are also required.
    Keywords antibodies ; antineoplastic agents ; biocompatibility ; cancer therapy ; fibrin ; hypoxia ; malnutrition ; mice ; molecular weight ; neoplasms ; oxidative stress ; permeability
    Language English
    Dates of publication 2022-0620
    Publishing place Elsevier B.V.
    Document type Article
    Note Pre-press version
    ZDB-ID 632533-6
    ISSN 1873-4995 ; 0168-3659
    ISSN (online) 1873-4995
    ISSN 0168-3659
    DOI 10.1016/j.jconrel.2022.06.035
    Database NAL-Catalogue (AGRICOLA)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2055: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Cancer stromal targeting therapy to overcome the pitfall of EPR effect.

    Matsumura, Yasuhiro

    Advanced drug delivery reviews

    2020  Volume 154-155, Page(s) 142–150

    Abstract: Many animal experiments performed worldwide have proven EPR effects However, it is hard to say that the EPR effect works in clinical practice. In the case of hematological malignancies, the administered anticancer agents (ACA) can physically interact ... ...

    Abstract Many animal experiments performed worldwide have proven EPR effects However, it is hard to say that the EPR effect works in clinical practice. In the case of hematological malignancies, the administered anticancer agents (ACA) can physically interact with the malignant cells, making it easier to reflect in vitro data. In solid tumors, however, the extravasated ACAs must diffuse evenly within the whole tumor mass. Therefore, the cancer stroma and the tumor mass itself can be obstacles to drug delivery systems (DDS) including antibody therapeutics. We have demonstrated that hypercoagulability caused by cancer forms cancer stroma. We further showed that the more aggressive the cancer, the greater the deposition of insoluble fibrin (IF) in cancer tissue. In this background, we decided to create monoclonal antibody (mAb) that specifically binds to IF. After a long effort, a new and unique IF-specific mAb was developed. Subsequently, anti-IF mAb conjugated with an ACA using a V-L-K linker which can be cut by plasmin. Because plasmin is activated only during IF formation, the ACA is released from the ADC only when the conjugate is bound to the IF. The released ACA may readily get to cancer cells through the stromal obstacle because of its small size. The ACA also damages the capillary that nourish cancer cells. We have named this strategy cancer (CA) stroma (S) targeting (T) therapy, or CAST therapy.
    MeSH term(s) Animals ; Antibodies, Monoclonal/administration & dosage ; Blood Coagulation ; Drug Delivery Systems ; Fibrin/antagonists & inhibitors ; Humans ; Neoplasms/drug therapy ; Neoplasms/pathology
    Chemical Substances Antibodies, Monoclonal ; Fibrin (9001-31-4)
    Language English
    Publishing date 2020-07-08
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 639113-8
    ISSN 1872-8294 ; 0169-409X
    ISSN (online) 1872-8294
    ISSN 0169-409X
    DOI 10.1016/j.addr.2020.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2241: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: An upper arm ganglion cyst connected to the bicipital groove associated with glenohumeral osteoarthritis: a case report.

    Tsujisaka, Ryosuke / Matsumura, Noboru / Kamata, Yusaku / Morioka, Hideo / Kiyota, Yasuhiro / Suzuki, Taku / Iwamoto, Takuji

    JSES reviews, reports, and techniques

    2024  Volume 4, Issue 2, Page(s) 272–275

    Language English
    Publishing date 2024-02-16
    Publishing country Netherlands
    Document type Case Reports
    ISSN 2666-6391
    ISSN (online) 2666-6391
    DOI 10.1016/j.xrrt.2024.01.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Characterization of antibody clones that bind exclusively to insoluble fibrin.

    Fuchigami, Hirobumi / Matsumura, Yasuhiro

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

    2022  Volume 34, Issue 1, Page(s) 20–27

    Abstract: Previously, we established an antibody, termed 102-10, which recognizes insoluble fibrin exclusively, unlike the previously established anti-insoluble fibrin antibodies that also cross-reacted with fibrinogen. We established that the epitope of this ... ...

    Abstract Previously, we established an antibody, termed 102-10, which recognizes insoluble fibrin exclusively, unlike the previously established anti-insoluble fibrin antibodies that also cross-reacted with fibrinogen. We established that the epitope of this antibody is on the β chain that lines an indented structure that becomes exposed only when insoluble fibrin is formed. The amino acid sequence of the epitope is completely conserved from mouse to humans. This study attempted to determine the most suitable insoluble fibrin clone for future diagnostic and therapeutic development. Binding kinetics and properties of antibodies were evaluated by the surface plasmon resonance analysis (SPR) and ELISA among 1101, 99, 443, and 102-10. Immunohistochemical staining for mouse and human pancreatic cancer tissues were also performed. For frozen sections, visually appropriate staining results were observed at an antibody concentration of 1-10 μg/ml, while for paraffin sections, 10 μg/ml was required. From immunohistochemistry and ELISA analyses, clone 99 and clone 1101 showed almost no nonspecific binding in normal pancreatic tissues. Hybridoma production for 1101 yielded more antibodies than that of 99 and demonstrated good long-term stability. It was, therefore, concluded that clone 1101 would be useful for future clinical development as well as basic research.
    MeSH term(s) Mice ; Humans ; Animals ; Fibrin/metabolism ; Antibodies, Monoclonal ; Fibrinogen/chemistry ; Epitopes/analysis ; Clone Cells/chemistry ; Clone Cells/metabolism
    Chemical Substances Fibrin (9001-31-4) ; Antibodies, Monoclonal ; Fibrinogen (9001-32-5) ; Epitopes
    Language English
    Publishing date 2022-11-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 1033551-1
    ISSN 1473-5733 ; 0957-5235
    ISSN (online) 1473-5733
    ISSN 0957-5235
    DOI 10.1097/MBC.0000000000001171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2920: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Synthesis of two optically active V-shaped molecules: Investigating the correlation between the stacking angle and chiroptical properties

    Matsumura, Kensei / Inoue, Ryō / Morisaki, Yasuhiro

    Tetrahedron. 2023 Apr. 06, p.133406-

    2023  , Page(s) 133406–

    Abstract: This study demonstrates the synthesis of two optically active V-shaped molecules using enantiopure pseudo-ortho- and pseudo-meta-disubstituted [2.2]paracyclophane as the chiral building blocks. Both consist of the same π-electron system (p-phenylene- ... ...

    Abstract This study demonstrates the synthesis of two optically active V-shaped molecules using enantiopure pseudo-ortho- and pseudo-meta-disubstituted [2.2]paracyclophane as the chiral building blocks. Both consist of the same π-electron system (p-phenylene-ethynylene containing three benzenes) stacked at the terminal benzene rings with stacking angles of 60° and 120°, respectively. The chiroptical properties, particularly the circularly polarized luminescence behavior, of the molecule with a stacking angle of 60° were better than those of its counterpart, and these results were confirmed via theoretical studies. A correlation exists between the chiroptical properties and stacking angle of emissive π-conjugated molecules.
    Keywords benzene ; enantiomers ; luminescence ; Cyclophane ; Planar chirality ; Circularly polarized luminescence
    Language English
    Dates of publication 2023-0406
    Publishing place Elsevier Ltd
    Document type Article ; Online
    Note Pre-press version
    ZDB-ID 204285-x
    ISSN 1464-5416 ; 0040-4020 ; 0563-2064
    ISSN (online) 1464-5416
    ISSN 0040-4020 ; 0563-2064
    DOI 10.1016/j.tet.2023.133406
    Database NAL-Catalogue (AGRICOLA)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1076: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top